118 related articles for article (PubMed ID: 19496180)
21. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway.
Rajesh KG; Suzuki R; Maeda H; Yamamoto M; Yutong X; Sasaguri S
J Mol Cell Cardiol; 2005 Nov; 39(5):766-76. PubMed ID: 16171810
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.
Qiao L; Yacoub A; Studer E; Gupta S; Pei XY; Grant S; Hylemon PB; Dent P
Hepatology; 2002 Apr; 35(4):779-89. PubMed ID: 11915023
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP.
Oh HY; Namkoong S; Lee SJ; Por E; Kim CK; Billiar TR; Han JA; Ha KS; Chung HT; Kwon YG; Lee H; Kim YM
Cell Death Differ; 2006 Mar; 13(3):512-23. PubMed ID: 16167066
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
Botla R; Spivey JR; Aguilar H; Bronk SF; Gores GJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):930-8. PubMed ID: 7853211
[TBL] [Abstract][Full Text] [Related]
26. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture.
Hillaire S; Ballet F; Franco D; Setchell KD; Poupon R
Hepatology; 1995 Jul; 22(1):82-7. PubMed ID: 7601437
[TBL] [Abstract][Full Text] [Related]
27. Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes.
Solá S; Castro RE; Kren BT; Steer CJ; Rodrigues CM
Biochemistry; 2004 Jul; 43(26):8429-38. PubMed ID: 15222754
[TBL] [Abstract][Full Text] [Related]
28. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of photodynamic therapy by ursodeoxycholic acid.
Kessel D; Caruso JA; Reiners JJ
Cancer Res; 2000 Dec; 60(24):6985-8. PubMed ID: 11156400
[TBL] [Abstract][Full Text] [Related]
30. Oleic Acid Protects against Hepatic Ischemia and Reperfusion Injury in Mice by Inhibiting AKT/mTOR Pathways.
Guo J; Zhang T; Gu J; Cai K; Deng X; Chen K; Huang K; Wang G; Li H; Wang J
Oxid Med Cell Longev; 2019; 2019():4842592. PubMed ID: 31915509
[TBL] [Abstract][Full Text] [Related]
31. The overall fatty acid absorption controlled by basolateral chylomicron excretion under regulation of p-JNK1.
Stremmel W; Staffer S; Wannhoff A; Pathil A
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):917-928. PubMed ID: 28602806
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes.
Azzaroli F; Mehal W; Soroka CJ; Wang L; Lee J; Crispe IN; Boyer JL
Hepatology; 2002 Jul; 36(1):49-54. PubMed ID: 12085348
[TBL] [Abstract][Full Text] [Related]
33. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
34. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.
Imarisio C; Alchera E; Sutti S; Valente G; Boccafoschi F; Albano E; Carini R
Clin Sci (Lond); 2012 Sep; 123(5):323-32. PubMed ID: 22439844
[TBL] [Abstract][Full Text] [Related]
35. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes.
Solá S; Amaral JD; Castro RE; Ramalho RM; Borralho PM; Kren BT; Tanaka H; Steer CJ; Rodrigues CM
Hepatology; 2005 Oct; 42(4):925-34. PubMed ID: 16175607
[TBL] [Abstract][Full Text] [Related]
36. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
37. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
38. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
40. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat.
Rodríguez-Ortigosa CM; Banales JM; Olivas I; Uriarte I; Marín JJ; Corrales FJ; Medina JF; Prieto J
Hepatology; 2010 Aug; 52(2):667-77. PubMed ID: 20683964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
